Metastasis and Disseminated Xenograft Models

Metastasis accounts for the majority of cancer mortality, yet the subcutaneous flank xenograft models only localized tumor growth. Metastasis and disseminated models address the steps of the metastatic cascade directly. Two distinct experimental strategies are used, and because they interrogate different parts of the cascade, choosing the wrong one produces a negative result for reasons that have nothing to do with the compound.

Altogen Labs establishes both experimental and spontaneous metastasis models, together with disseminated hematologic models, in an IACUC-regulated facility. Reporter-tagged lines for longitudinal imaging are available or can be generated through reporter stable cell line development. To discuss which configuration fits a mechanism, request a quote.

Experimental metastasis models

Tumor cells are delivered intravascularly, bypassing the early steps of the cascade and interrogating the later ones: survival in circulation, arrest, extravasation, and colonization of a distant organ. Route determines which organ is seeded, and the resulting pattern is reproducible, which is the principal advantage of the approach.

Tail vein injection delivers cells to the pulmonary vasculature and generates lung colonization. Intracardiac injection into the left ventricle distributes cells arterially and is the standard route for bone and brain colonization. Intrasplenic injection delivers cells through the portal circulation to the liver. Each route produces a defined pattern of organ involvement on a predictable timeline, which makes the readout quantitative and the study straightforward to power.

The corresponding limitation is fundamental rather than technical. These models say nothing about local invasion or intravasation, because those steps have been bypassed. An agent that blocks early dissemination will show no benefit in an experimental metastasis model, and that null result would be an artifact of the design rather than a property of the compound.

Spontaneous metastasis models

An orthotopic primary tumor is established and allowed to disseminate through the complete cascade: local invasion, intravasation, survival in circulation, extravasation, and colonization. This is the more faithful representation of clinical progression and the only configuration in which an anti-invasive or anti-intravasation mechanism can be demonstrated.

The trade-offs are time and variability. Spontaneous models require longer study durations, metastatic burden varies more between animals than in experimental models, and in many configurations the primary tumor reaches a humane endpoint before metastatic disease is fully established. Primary tumor resection is used in some designs to extend the window during which metastatic progression can be observed, at the cost of an additional surgical procedure.

Disseminated and systemic hematologic models

Hematologic malignancies are modeled by intravenous injection of leukemia or lymphoma cells, which home to bone marrow, spleen, and other hematopoietic compartments and produce systemic disease. These models are the standard preclinical platform for cell therapy evaluation, where the therapeutic question concerns trafficking, persistence, and clearance of disseminated tumor rather than shrinkage of a discrete mass.

Quantification

Metastatic burden cannot be measured with calipers, so quantification depends on choices made at design stage. Bioluminescent imaging of reporter-tagged lines permits longitudinal whole-body assessment with organ-level localization. Terminal approaches include ex vivo organ imaging, macroscopic surface nodule counts, histological quantification of metastatic foci, and species-specific quantitative PCR for human DNA in murine tissue where sensitivity below the imaging threshold is required. Survival and time to endpoint are frequently the most interpretable primary endpoints.

Endpoint definitions, imaging schedule, organ panel, and quantification method are specified before initiation, since metastasis endpoints are considerably more sensitive to analytic choices than volume endpoints and post hoc selection among them is not defensible.

Applied examples

Lung colonization. A breast cancer line is delivered by tail vein injection and treatment begins twenty-four hours later, with pulmonary burden followed by imaging and confirmed at necropsy by surface nodule count, addressing whether the agent prevents colonization of an already-seeded organ.

Bone metastasis. A prostate line is delivered by intracardiac injection, with skeletal lesions localized by imaging and assessed histologically at endpoint for osteolytic change alongside tumor burden.

Anti-invasive mechanism. An agent proposed to block intravasation is tested in a spontaneous model rather than an experimental one, since the mechanism of interest operates upstream of the step an intravascular model begins at.

Welfare considerations in systemic disease

All procedures are conducted under active IACUC protocols. Disseminated and metastatic models require humane endpoints defined against clinical signs rather than tumor dimension, since animals may reach a welfare endpoint without any measurable mass. Protocols specify monitoring frequency, clinical scoring criteria, and the specific signs that trigger removal from study, and monitoring intensifies as the study progresses. GLP standards are applied where a study is formally designated as GLP.

Send cell line, target organ, and mechanism details, or request a quote.